1. Home
  2. RGT vs NVNO Comparison

RGT vs NVNO Comparison

Compare RGT & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

HOLD

Current Price

$12.99

Market Cap

83.2M

Sector

Finance

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

HOLD

Current Price

$0.33

Market Cap

16.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGT
NVNO
Founded
1986
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.2M
16.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RGT
NVNO
Price
$12.99
$0.33
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
22.4K
503.6K
Earning Date
01-01-0001
10-31-2025
Dividend Yield
1.43%
N/A
EPS Growth
N/A
N/A
EPS
0.92
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.84
$0.30
52 Week High
$11.08
$5.62

Technical Indicators

Market Signals
Indicator
RGT
NVNO
Relative Strength Index (RSI) 65.66 35.38
Support Level $12.72 $0.31
Resistance Level $12.92 $0.38
Average True Range (ATR) 0.13 0.04
MACD 0.03 0.01
Stochastic Oscillator 72.55 28.11

Price Performance

Historical Comparison
RGT
NVNO

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: